ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,556,283 | -44.5% | 3,117,944 | -0.3% | 0.12% | -18.0% |
| Q2 2023 | $29,807,715 | -13.6% | 3,127,777 | -0.2% | 0.15% | -33.0% |
| Q1 2023 | $34,490,643 | +16.2% | 3,135,513 | +56.3% | 0.22% | -5.5% |
| Q4 2022 | $29,685,500 | +18.6% | 2,005,777 | +53.2% | 0.24% | +49.1% |
| Q3 2022 | $25,020,000 | -16.5% | 1,309,268 | -6.9% | 0.16% | -9.7% |
| Q2 2022 | $29,958,000 | -12.8% | 1,405,796 | -21.2% | 0.18% | +13.5% |
| Q1 2022 | $34,360,000 | -7.1% | 1,784,005 | 0.0% | 0.16% | +11.5% |
| Q4 2021 | $37,000,000 | -0.0% | 1,784,005 | +15.2% | 0.14% | -7.9% |
| Q3 2021 | $37,003,000 | -19.4% | 1,548,901 | -7.9% | 0.15% | -24.1% |
| Q2 2021 | $45,917,000 | +1.9% | 1,682,543 | +8.0% | 0.20% | -28.7% |
| Q1 2021 | $45,060,000 | +106.7% | 1,557,543 | +101.0% | 0.28% | +111.4% |
| Q4 2020 | $21,801,000 | – | 775,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |